The Croatian Model of NIH criteria Implementation

Size: px
Start display at page:

Download "The Croatian Model of NIH criteria Implementation"

Transcription

1 The Croatian Model of NIH criteria Implementation Lana Grkovic, MD, UHC Zagreb, Zagreb, Croatia October 2014, Warsaw, Poland #EBMT2014

2 History of transplant at UHC Zagreb Haplo children Haplo AlloBMT Related donor MAC Autologous BMT UC 1989 AlloBMT Urelated donor 1992 HLA DNA-based RIC

3 AlloBMT at UHC Zagreb

4 RIC MAC

5 unrelated related 5 5

6 Organization of cgvhd program and clinical activity of the multidisciplinary team Visit of Prof. SZ Pavletic to the UHC Zagreb 6 6

7 Multidisciplinary team Professionals from a range of disciplines who work together to deliver comprehensive care that addresses as many of the patient's needs as possible. As a patient's condition changes over time, the composition of the team may change to reflect the changing clinical and psychosocial needs of the patient. Mitchell, G.K., Tieman, J.J. & Shelby-James, T.M. (2008). Multidisciplinary care planning and teamwork in primary care. MJA, 188(8), p.s

8 Results: Established cgvhd multidisciplinary team 8 8

9 Team members Hematology: Damir Nemet, Dražen Pulanić, Lana Grković, Ranka Serventi-Seiwerth, Radovan Vrhovac, Nadira Duraković, Zinaida Perić Pediatric Hematology: Ljubica Rajić, Ernest Bilić Nurse: Nikolina Matić Dental: Marinka Mravak Stipetić Neurology: Ervina Bilić Dermatology: Romana Čeović Ophthalmology: Igor Petriček PT: Tamara Vukić Gynecology: Tajana Klepac Pulanić, Slavko Orešković Nutritional: Dina Ljubas Immunology: Drago Batinić Transfusiology: Ines Bojanić ID: Davorka Dušek, Adriana Vince Molecular: Magdalena Grce, Renata Zadro GI: Željko Krznarić Pathology: Ivana Ilić Endocrinology: Zlatko Giljević HLA: Zorana Grubić PhD student: Ema Prenc Postdoc Iva Prah Steven Živko Pavletić- Collaborator 9 9

10 Day Hospital (Center for cgvhd and long term complications) 10 10

11 11 11

12 12 12

13 13 13

14 IRB approved informed consent signing H&P Laboratory workup Standard forms (NIH core sheet, form A and B..) Neurologic assessment and pain questionnaire QoL SF-36, Lee symptom scale, QLQ-C

15 cgvhd multidisciplinary team HEMATOLOGY DERMATOLOGY NUTRITION DENTAL PHYSICAL THERAPY HEPATOLOGY/GI ENDOCRINOLOGY PATIENT PULMONARY OPHTALMOLOGY INFECTIOUS DISEASE TRANSFUSIOLOGY GYNECOLOGY NEUROLOGY 15 15

16 Our results 16 16

17 17 17

18 QLQ-C30 = 30 questions five multi-item functional scales (Physical, Role, Emotional, Cognitive and Social Functioning) + combined Global Health Status/QoL scale Higher scores signify better functioning Nine symptom scales measure fatigue, pain, nausea,vomiting, dyspnea, sleep disturbances, appetite loss, diarrhoea, constipation and financial impact Higher scores represent greater symptomatology or impairments 18 18

19 Evaluation of QOL at UHC Zagreb SF-36 Results 19 19

20 Evaluation of QOL at UHC Zagreb QLQ- C30 Results 20 20

21 21 21

22 Ministry of science education and sports of the Republic of Croatia; Unity Through Knowledge Fund Project (2 years) Project title: Clinical and biological factors determining severity and activity of chronic Graft-versus-Host Disease after allogeneic hematopoietic stem cell transplantation Approx. $ 300, 000 (funded by World Bank and Ministry) Project Leader and Co-leader : prof. SZ Pavletic i prof. D. Nemet 8 Institutions participating: NCI/NIH, Medical School University of Zagreb, UHC Zagreb, School of Dental Medicine Zagreb, Institute Ruđer Bošković, KROHEM, University Hospital for Infectious Disease Dr. Fran Mihaljevic 22 22

23 CONNECTIVITY, COOPERABILITY, CREATIVITY C3 Mission: To unite scientific and professional potential in Croatia and Diaspora in development of the knowledge based society Goals: Ministry of science education and sports of the Republic of Croatia-Crossing Borders Grant; Unity Through Knowledge Fund Project 1) Supporting research that is competitive on international level 2) Fostering research that creates new values in Croatian economy 3) Supporting projects that help the development of research infrastructure in Croatia 23 23

24 Aims: Crossing Borders Grant To support outstanding Croatian scientists and professionals working and living abroad (Diaspora) in establishing scientific cooperation with local scientists (Croatian and foreign scientists working and living in Croatia), To foster Croatian institutions and enterprises to use potentials of Croatian scientific and professional Diaspora transfer of knowledge and attract investments to Croatian organization through cooperation between Diaspora and local scientists

25 Goals Establishment of the multidisciplinary team Comprehensive clinical, laboratory and imaging evaluation using NIH Consensus criteria Subspeciality evaluations focused on affected organs Creation of database and tissue and sera bank Subprojects New grant proposal application; collaboration with other Centers 25 25

26 First year results 32 cgvhd patients enrolled and 4 controls 8 abstracts published Oral presentation - Croatian society of hematology and transfusiology meeting with international participation, Rovinj, Croatia, March 2014 Grkovic L., Pulanic D., Serventi-Seiwerth R., Matic N., Mravak-Stipetic M., Ceovic R., Bilic E., Ljubas D., Rajic Lj., BIlic E., Durakovic N., Peric Z., Kovac K., Klepac Pulanic T., Dusek D., Bojanic I., Grce M., Petricek I., Batinic D., Vrhovac R., Pavletic S. Z., Nemet D. Formiranje multidisciplinarnog tima za liječenje kronične reakcije davatelja protiv primatelja i dugotrajnih komplikacija nakon transplantacije alogenih krvotvornih matičnih stanica u Kliničkom bolničkom centru Zagreb. Liječ Vjesn. 2014;136 (Supl 1.):

27 4 poster presentations Croatian society of hematology and transfusiology meeting with international participation, Rovinj, Croatia, March 2014 Bilić E., Grković L., Pulanić D., Serventi Seiwerth R., Bilić E., Vrhovac R., Nemet D., Pavletic SZ. Polyneuropathy in cgvhd patients Preliminar results. Liječ Vjesn. 2014;136 (Supl 1.):87. PRIZE FOR THE BEST POSTER Ljubas Kelecic D., Vranesic Bender D., Krznaric Z., Grkovic L., Pavletic S., Nemet D., Serventi Seiwerth R., Vrhovac R., Pulanic D. Nutritional status in patients with chronic GVHD. Liječ Vjesn. 2014;136 (Supl 1.):135. Pulanic D, Mravak-Stipetić M., Grkovic L., Serventi Seiwerth R., Vrhovac R., Nemet D., Sabol I., Grce M., Pavletic SZ. Oral manifestations in u cgvhd patients. Liječ Vjesn. 2014;136 (Supl 1.):89. Perić Z., Grkovic L., Pulanic D., Serventi-Seiwerth R., Matic N., Mravak-Stipetic M., Bilic E., Ceovic R., Ljubas D., Rajic Lj., BIlic E., Durakovic N., Klepac Pulanic T., Kovac K., Dusek D., Bojanic I., Grce M., Batinic D., Vrhovac R., Pavletic SZ., Nemet D. Quality of life after allogeneic stem cell transplantation. Liječ Vjesn. 2014;136 (Supl 1.):

28 EBMT, Milano, Italy, April L. Grkovic, D. Pulanic, R. Serventi-Seiwerth, N. Matic, M. Mravak-Stipetic, E. Bilic, R. Ceovic, D. Ljubas, Lj. Rajic, E. Bilic, N. Durakovic, Z. Peric, T. Klepac Pulanic, K. Kovac, D. Dusek, I. Bojanic, M. Grce, D. Batinic, R. Vrhovac, S.Z. Pavletic, D. Nemet. Implementation and dissemination of chronic Graft-versus-Host Disease NIH criteria and recommendations - formation of a multidisciplinary team and program at the University Hospital Center Zagreb, Croatia. Bone Marrow Transplant 49: S101-S385 (March 2014); doi: /bmt POSTER PRESENTATION M. Mravak-Stipetic, L. Grkovic, D. Pulanic, I. Sabol, M. Grce, D. Nemet, SZ Pavletic. Comprehensive evaluation of oral chronic graft versus host disease (cgvhd) in a cohort of Croatian patients. Bone Marrow Transplant 49: S438-S559 (March 2014); doi: /bmt PUBLICATION ONLY 28 28

29 Oral pressentation at international meeting EFNS-ENS Joint Congress of European Neurology May E. Bilic, L. Grkovic, D. Pulanic, E. Bilic, D. Nemet, SZ Pavletic. Small fiber neuropathy in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation - preliminary results of a prospective study. Europ J Neurology Abstract supplement,

30 Subprojects: Oral GVHD (trombocyte gel from autologous blood) Infections in cgvhd patients (HPV, EBV, CMV, polyoma virus, Candida albicans) Neurological cgvhd manifestations small fiber neuropathy (ENG and QST; pain detect questionnaire) Genital cgvhd Immunology (monocyte analysis from leukapheresis product; (CD16/CD163 i CD64/CD80) 30 30

31 Training at NIH, NCI Croatian members of cgvhd team (Past): Assist. Prof. Drazen Pulanic, MD, PhD (1 year) Ranka Serventi-Seiwerth, MD (3 months) Lana Grkovic, MD (1 year) PhD student and Post Doc hired (Present) PhD student visit to National Institutes of Health (Sep 2014) 31 31

32 Dissemination of the project results Web page 32 32

33 Interview; Croatian National Television 33 33

34 International Symposium Chronic GVHD and long term complications after hematopoietic stem cell transplantation, Zagreb, November

35 35 35

36 36 36

37 Development of the original database 37 37

38 Proposal submitted 38 38

39 Call PHC : Understanding common mechanisms of diseases and their relevance in comorbidities 39 39

40 Conclusions Multidisciplinary team established Comprehensive clinical, laboratory and imaging evaluation using NIH criteria Scientific activity Database developed PhD sudent and Postdoc hired New grant proposal submitted (HORIZON 2020) 40 40

41 THANK YOU! 41

PLATELETS AND COAGULATION IN CHRONIC GRAFT VERSUS HOST DISEASE

PLATELETS AND COAGULATION IN CHRONIC GRAFT VERSUS HOST DISEASE UDK 616.155.2 Review article Received: 4 June 2015 Accepted: 16 September 2015 PLATELETS AND COAGULATION IN CHRONIC GRAFT VERSUS HOST DISEASE Dražen Pulanić a,b,c a Division of Hematology, University Department

More information

Impressum Bilten Krohema Publisher: For publisher: Editor in Chief: Secretary of the Editorial Board: Editorial Board: Secretary of the CROHEM:

Impressum Bilten Krohema Publisher: For publisher: Editor in Chief: Secretary of the Editorial Board: Editorial Board: Secretary of the CROHEM: Impressum Bilten Krohema The Journal of the Croatian Cooperative Group for Hematological Diseases CROHEM Volume 8, Supplement 1, September 2016 Publisher: Croatian Cooperative Group for Hematological Diseases

More information

4nd Patient and Family Day

4nd Patient and Family Day 4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,

More information

Protecting Your Health After Transplant (Adults)

Protecting Your Health After Transplant (Adults) Protecting Your Health After Transplant (Adults) Navneet Majhail, MD, MS Medical Director, Health Services Research, National Marrow Donor Program Adjunct Associate Professor of Medicine, University of

More information

PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey

PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey Joint Educational Meeting of the EBMT Severe Aplastic Anaemia, Late Effects and Autoimmune Diseases Working Parties

More information

Nothing to disclose. Title of the presentation - Author

Nothing to disclose. Title of the presentation - Author Nothing to disclose Title of the presentation - Author 1 www.ebmt.org Complications after HSCT Alicia Rovó MD London 9/04/2013 Introduction Risk factors for transplant complication Type of complications

More information

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts

More information

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant

More information

Introduction. Graft Versus Host Disease: Living With the After Effects of Bone Marrow/Stem Cell Transplant

Introduction. Graft Versus Host Disease: Living With the After Effects of Bone Marrow/Stem Cell Transplant Graft Versus Host Disease: Living With the After Effects of Bone Marrow/Stem Cell Transplant Introduction Chronic Graft versus Host Disease (cgvhd) occurs after a transplant when the immune system of the

More information

Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life

Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life 1 Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life Stephanie J. Lee, MD, MPH Fred Hutchinson Cancer Research Center April 16, 2016 (40 min) Hematopoietic

More information

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state

More information

National Drugs Monitoring System in Croatia (JHA 53303)

National Drugs Monitoring System in Croatia (JHA 53303) TAIEX workshop on National Drugs Monitoring System in Croatia (JHA 53303) organised by TAIEX (Technical Assistance and Information Exchange Instrument) of the European Commission, in co-operation with

More information

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

More information

The Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014

The Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014 The Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014 Worldwide Network for Blood and Marrow Transplantation Transplants A Little

More information

Sylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1.

Sylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1. Bone Marrow Research Volume 2012, Article ID 873695, 5 pages doi:10.1155/2012/873695 Clinical Study Both Optimal Matching and Procedure Duration Influence Survival of Patients after Unrelated Donor Hematopoietic

More information

Late complications after hematopoietic stem cell transplant in adult patients

Late complications after hematopoietic stem cell transplant in adult patients Late complications after hematopoietic stem cell transplant in adult patients Gérard Socié, MD, PhD Hematology/Transplantation, Hospital Saint Louis, Paris, France Synopsis H S C T Allogeneic HSCT activity

More information

Developing a Quality Dashboard An Evidence Based Approach PURPOSE/OBJECTIVES:

Developing a Quality Dashboard An Evidence Based Approach PURPOSE/OBJECTIVES: Developing a Quality Dashboard An Evidence Based Approach PURPOSE/OBJECTIVES: 1. To discuss the process that NYUHC Oncology Nursing Services used to develop and maintain a quality dashboard. 2. To define

More information

EBMT Complications and Quality of Life Working Party Educational Course

EBMT Complications and Quality of Life Working Party Educational Course EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life

More information

Neglected deficiencies in severe malnutrition: phosphate and thiamine Case-based introduction A-M. Liberati-Cizmek (Croatia)

Neglected deficiencies in severe malnutrition: phosphate and thiamine Case-based introduction A-M. Liberati-Cizmek (Croatia) ESPEN Congress Vienna 2009 Neglected deficiencies in severe malnutrition: phosphate and thiamine Case-based introduction A-M. Liberati-Cizmek (Croatia) Neglected deficiencies in severe malnutrition: thiamine

More information

Disclosure. Objectives 1/22/2015

Disclosure. Objectives 1/22/2015 Evaluation of the Impact of Anti Thymocyte Globulin (ATG) on Post Hematopoietic Stem Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Katie S. Kaminski, PharmD, CPP University of North

More information

Joint and fascial chronic graftvs-host disease: correlations with clinical and laboratory parameters

Joint and fascial chronic graftvs-host disease: correlations with clinical and laboratory parameters 266 GRAFT-VS-HOST DISEASE Croat Med J. 2016;57:266-75 doi: 10.3325/cmj.2016.57.266 Joint and fascial chronic graftvs-host disease: correlations with clinical and laboratory parameters Aim To determine

More information

Objectives. Describe a multidisciplinary team and it s utilization in the inpatient cardiovascular surgical patient

Objectives. Describe a multidisciplinary team and it s utilization in the inpatient cardiovascular surgical patient None Endorsements Objectives Describe a multidisciplinary team and it s utilization in the inpatient cardiovascular surgical patient Understand clinical and clinician benefits of a multidisciplinary team

More information

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016 Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this

More information

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient 1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical

More information

Survivorship After Stem Cell Transplantation and Long-term Followup

Survivorship After Stem Cell Transplantation and Long-term Followup Survivorship After Stem Cell Transplantation and Long-term Followup Navneet Majhail, MD, MS Director, Blood & Marrow Transplant Program, Cleveland Clinic Professor, Cleveland Clinic Lerner College of Medicine

More information

Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017

Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017 Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell Ann Haight, MD 9 Sept 2017 Spoiler alert Yes (we have a cure) And No Work to do! 2 Sickle Cell Treatment Options Supportive Care

More information

Donatore HLA identico di anni o MUD giovane?

Donatore HLA identico di anni o MUD giovane? Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events

More information

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize

More information

Twenty-five-years history of the Department of Immunology at the Children s Memorial Health Institute in Warsaw

Twenty-five-years history of the Department of Immunology at the Children s Memorial Health Institute in Warsaw Immunological forum Twenty-five-years history of the Department of Immunology at the Children s Memorial Health Institute in Warsaw EWA BERNATOWSKA This year the Department of Immunology at the Children

More information

NEWS FROM. Roswell Park s BLOOD AND MARROW TRANSPLANT PROGRAM

NEWS FROM. Roswell Park s BLOOD AND MARROW TRANSPLANT PROGRAM NEWS FROM Roswell Park s BLOOD AND MARROW TRANSPLANT PROGRAM THE BLOOD AND MARROW TRANSPLANT TEAM Philip McCarthy, MD Medical Director, BMT Program Hong Liu, MD, PhD Attending Physician Our multidisciplinary

More information

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1 Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,

More information

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte

More information

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates

More information

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant

More information

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell

More information

How to prevent Infections in Patients undergoing allo-hsct?

How to prevent Infections in Patients undergoing allo-hsct? How to prevent Infections in Patients undergoing allo-hsct? Olaf Penack EBMT Course, 29 Sept 1 Oct 2014, Naples, Italy #EBMT2014 www.ebmt.org Prevention of Infections Epidemiology and risk factors for

More information

Integrating Palliative and Oncology Care in Patients with Advanced Cancer

Integrating Palliative and Oncology Care in Patients with Advanced Cancer Integrating Palliative and Oncology Care in Patients with Advanced Cancer Jennifer Temel, MD Massachusetts General Hospital Cancer Center Director, Cancer Outcomes Research Overview 1. Why should we be

More information

Late Complications. Objectives. Long-term Survival after HCT. Long-term Survival and Late Complications after HCT. Long-term Survival after HCT

Late Complications. Objectives. Long-term Survival after HCT. Long-term Survival and Late Complications after HCT. Long-term Survival after HCT Objectives Late Complications Navneet Majhail, MD, MS Review late complications in hematopoietic cell transplant (HCT) recipients Review screening and prevention guidelines for HCT survivors Review upcoming

More information

Late Complications. Navneet Majhail, MD, MS

Late Complications. Navneet Majhail, MD, MS Late Complications Navneet Majhail, MD, MS Medical Director, Health Services Research, NMDP Assistant Scientific Director, CIBMTR Adjunct Associate Professor of Medicine University of Minnesota Objectives

More information

Workshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan

Workshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Workshop I: Patient Selection Current indication for HCT in adults Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Factors to Take into Account with Recommending HCT Patient & disease factors

More information

Le infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy

Le infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator

More information

Donor work up, follow up and ethical issues

Donor work up, follow up and ethical issues Donor work up, follow up and ethical issues Hans Hägglund MD. PhD. Associate Professor Hematology Center, Karolinska University Hospital, Stockholm, Sweden Outline The donor has been identified as a match

More information

Stem cell transplantation. Dr Mohammed Karodia NHLS & UP

Stem cell transplantation. Dr Mohammed Karodia NHLS & UP Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From

More information

Research Status up to Date

Research Status up to Date (File of Details of Application) 2. Research Status up to Date (Describe the status specifically; chart/diagram may be included. Change/addition of the form is not allowed. (The same shall apply hereafter))

More information

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000

More information

EBV in HSCT 2015 update of ECIL guidelines

EBV in HSCT 2015 update of ECIL guidelines ECIL-6 EBV in HSCT 2015 update of ECIL guidelines Jan Styczynski (Poland, chair), Walter van der Velden (Netherlands), Christopher Fox (United Kingdom), Dan Engelhard (Israel), Rafael de la Camara (Spain),

More information

CARE-NMD results. Jan Kirschner

CARE-NMD results. Jan Kirschner CARE-NMD results Jan Kirschner TREAT-NMD Alliance Meeting Newcastle 30 Oct -1 Nov 2013 Care recommendations for DMD Consensus process 2 Care recommendations for DMD Consensus process Scientific publication

More information

Clinical Trials: Questions and Answers

Clinical Trials: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Clinical Trials: Questions

More information

Lynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines

Lynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines Lynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines 3. WBMT Workshop 14-15 November 2014 Cape Town, South Africa Department for Hematology and Medical Oncology Leipzig,

More information

Related haploidentical donors versus matched unrelated donors

Related haploidentical donors versus matched unrelated donors Related haploidentical donors versus matched unrelated donors Bronwen Shaw, MD PhD Professor of Medicine, MCW Senior Scientific Director, CIBMTR Definition Matched Unrelated donor Refers to HLA matching

More information

AAP Immunization Initiatives JILL HERNANDEZ, MPH

AAP Immunization Initiatives JILL HERNANDEZ, MPH AAP Immunization Initiatives JILL HERNANDEZ, MPH AAP Structure The AAP Today 62,000 members 10 districts 66 state/local chapters 26 national committees 50 sections 11 councils 500 staff Illinois, Washington

More information

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,

More information

Rituximab, and autologous stem cell collection rate after induction therapy with Bortezomib-Rituximab. 4 Not yet recruiting

Rituximab, and autologous stem cell collection rate after induction therapy with Bortezomib-Rituximab. 4 Not yet recruiting 1 Recruiting A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Conditions: Waldenstrom's ; Waldenstrom Macroglobulinaemia Intervention: Biological: Ofatumumab Sponsor: GlaxoSmithKline Number

More information

Stem cell Survivorship: Searching for a solution to our success. Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic

Stem cell Survivorship: Searching for a solution to our success. Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic Stem cell Survivorship: Searching for a solution to our success Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic Location of Centers Participating in t he CI BMTR 2 0 0 7................................................................................................................

More information

Late effects after HSCT

Late effects after HSCT Late effects after HSCT Yves Chalandon Hematology Division, University Hospital of Geneva (HUG) Switzerland Hôpitaux Universitaires de Genève Company name Disclosures of: Yves Chalandon Research support

More information

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal

More information

Blood & Marrow Transplant Leukemia Immunotherapy

Blood & Marrow Transplant Leukemia Immunotherapy Blood & Marrow Transplant Leukemia Immunotherapy Our Physicians Our specially trained physicians provide leadership for the Northside Hospital Blood and Marrow Transplant, Leukemia and Immunotherapy Programs,

More information

ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015

ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM

More information

Reduced-intensity Conditioning Transplantation

Reduced-intensity Conditioning Transplantation Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,

More information

Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University

Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Graft-versus-Host Disease (GVHD) Background GVHD is an immunologic reaction of the donor immune cells (Graft) against

More information

87 Telemedicine sites

87 Telemedicine sites Children s - Largest Pediatric Provider in U.S. Scottish Rite Egleston Hughes Spalding 28 7 Neighborhood Locations Urgent Care Centers 87 Telemedicine sites 1 We re Growing Outpatient Care Center at Town

More information

Haploidentical Transplantation today: and the alternatives

Haploidentical Transplantation today: and the alternatives Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks

More information

Office of Clinical Research Annual Report 2017 July 1, June 30, 2017

Office of Clinical Research Annual Report 2017 July 1, June 30, 2017 Office of Clinical Research Annual Report 2017 July 1, 2016- June 30, 2017 Table of Contents Title Page Number Mission Statement 1 Objective 1 Research Services 1 Research Highlights 2 Figure 1 Number

More information

Michael Grimley 1, Vinod Prasad 2, Joanne Kurtzberg 2, Roy Chemaly 3, Thomas Brundage 4, Chad Wilson 4, Herve Mommeja-Marin 4

Michael Grimley 1, Vinod Prasad 2, Joanne Kurtzberg 2, Roy Chemaly 3, Thomas Brundage 4, Chad Wilson 4, Herve Mommeja-Marin 4 Twice-weekly Brincidofovir (BCV, CMX1) Shows Promising Antiviral Activity in Immunocompromised Transplant Patients with Asymptomatic Adenovirus Viremia Michael Grimley 1, Vinod Prasad, Joanne Kurtzberg,

More information

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,

More information

World Premier International Research Center (WPI) Initiative General Comments on FY2007 WPI Project Progress by Program Committee

World Premier International Research Center (WPI) Initiative General Comments on FY2007 WPI Project Progress by Program Committee World Premier International Research Center (WPI) Initiative General Comments on FY2007 WPI Project Progress by Program Committee WPI Research Centers In October 2007, the Ministry of Education, Culture,

More information

Back to the Future: The Resurgence of Bone Marrow??

Back to the Future: The Resurgence of Bone Marrow?? Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow

More information

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest

More information

EBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation

EBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation EBMT EBMT Organisation and Activities J Apperley 13th. ESH-EBMT Training Course Targu Mures May 24 26, 2010 History Organisation Studies Activity Philosophy EBMT Website www.ebmt.org EBMT Society European

More information

COPING STRATEGIES IN CHILDREN WITH HEADACHES

COPING STRATEGIES IN CHILDREN WITH HEADACHES COPING STRATEGIES IN CHILDREN WITH HEADACHES Anita Vulić-Prtorić Department of Psychology, University of Zadar, Croatia Renata Coha Department of Pediatrics, General Hospital Josip Benčević, Slavonski

More information

ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology

ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology ACGME approved: June 27, 2006; effective: July 1, 2007 ACGME approved focused revision: September 30, 2012; effective:

More information

Disclosures. Investigator-initiated study funded by Astellas

Disclosures. Investigator-initiated study funded by Astellas Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development

More information

HAEMATOPOIETIC STEM CELL TRANSPLANTATION

HAEMATOPOIETIC STEM CELL TRANSPLANTATION PRIMARY IMMUNODEFICIENCIES HAEMATOPOIETIC STEM CELL TRANSPLANTATION HAEMATOPOIETIC STEM CELL TRANSPLANTATION 1 PRIMARY IMMUNODEFICIENCIES KEY ABBREVIATIONS CID GvHD HSCT IPOPI PID SCID BMT HSC Combined

More information

Bibliometric study on Dutch academic medical centers /2014

Bibliometric study on Dutch academic medical centers /2014 NFU-kenmerk: 5.783 Registratiedatum: 3-7-205 Bibliometric study on Dutch academic medical centers 998-203/204 Research report to the Deans of Medical Sciences (DMW) in the Netherlands June 205 Center for

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

National Center for Child Health and Development Organ Transplantation Center

National Center for Child Health and Development Organ Transplantation Center National Center for Child Health and Development Organ Transplantation Center A t the division of transplantation center in NCCHD, we have a mission to save children s life who have been suffered from

More information

Sickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?

Sickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD? Sickle Cell Diseasechronic illness or curable disease? Gregory M.T. Guilcher MD, FRCPC, FAAP Objectives To review the general principles of hematopoietic stem cell transplantation (HSCT), including risks

More information

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children s Research Hospital Departments of Hematology, Patient

More information

Blood & Marrow Transplantation Center

Blood & Marrow Transplantation Center Blood & Marrow Transplantation Center We were one of the first centers in the world to routinely offer patients blood and marrow transplantation (BMT). What Sets Us Apart High-volume center performs about

More information

the Office of Research Application Portal: Materials to submit:

the Office of Research Application Portal:   Materials to submit: Title: PAR 17 237: Centers for AIDS Research (P30) Slots: 1 Internal Deadline: LOI: External Deadline: Award Information: Submission Process: May 26, 2018, 5pm PDT 30 days prior to the application due

More information

State of the Art of Rare Disease Activities in EU Member States and Other European Countries Croatia Report

State of the Art of Rare Disease Activities in EU Member States and Other European Countries Croatia Report State of the Art of Rare Disease Activities in EU Member States and Other European Countries Croatia Report Definition of a Rare Disease Croatia has adopted the European Commission definition of a rare

More information

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions

More information

ASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS

ASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);

More information

Stem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT

Stem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT Stem cells -Dr Dinesh Bhurani, MD, DM, FRCPA -Director, Department of Haematology and BMT Rajiv Gandhi Cancer Institute, Delhi, Flow of presentation Update on stem cell uses Haematopoietic stem cell transplantation

More information

Stem Cell Transplantation for Severe Aplastic Anemia

Stem Cell Transplantation for Severe Aplastic Anemia Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center

More information

February Company Overview. Curative Treatments for Cancer and Orphan Genetic Diseases

February Company Overview. Curative Treatments for Cancer and Orphan Genetic Diseases February 2017 Company Overview Curative Treatments for Cancer and Orphan Genetic Diseases Curative Treatments for Orphan Indications NiCord - a bone marrow transplantation treatment for patients with high

More information

Blood and Marrow Transplant (BMT) for Sickle Cell Disease

Blood and Marrow Transplant (BMT) for Sickle Cell Disease Blood and Marrow Transplant (BMT) for Sickle Cell Disease Rhiannon is now cured of sickle cell disease after BMT. Blood and marrow transplant (BMT) is a proven cure for sickle cell disease. This handbook

More information

Current Status of Haploidentical Hematopoietic Stem Cell Transplantation

Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT

More information

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital

More information

Haplo vs Cord vs URD Debate

Haplo vs Cord vs URD Debate 3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor

More information

What s a Transplant? What s not?

What s a Transplant? What s not? What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence

More information

Bone Marrow Transplantation and the Potential Role of Iomab-B

Bone Marrow Transplantation and the Potential Role of Iomab-B Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation

More information

Fogarty Initiatives for Building Capacity in HIV/AIDS

Fogarty Initiatives for Building Capacity in HIV/AIDS Fogarty Initiatives for Building Capacity in HIV/AIDS April 13, 2010 Michael P. Johnson, M.D., M.P.H Deputy Director Fogarty International Center Global Health Transition in 21 st Century the unfinished

More information

Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale

Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale BMT CTN 1101 RIC ducb vs. Haplo Page 1 of 10 Date: January 20, 2017 Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, 2017 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC)

More information

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow 5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL

More information

Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients

Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France

More information

LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS

LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS Farid Boulad, Susan E Prockop, Praveen Anur, Danielle

More information

Integration of Acute and Chronic Graft-Versus-Host Disease Assessments into the Inpatient Electronic Medical Record

Integration of Acute and Chronic Graft-Versus-Host Disease Assessments into the Inpatient Electronic Medical Record Integration of Acute and Chronic Graft-Versus-Host Disease Assessments into the Inpatient Electronic Medical Record Madhu Ragupathi, MD Research Analyst II Charles A. Sammons Cancer Center at Baylor University

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle  holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/28461 holds various files of this Leiden University dissertation. Author: Brink, Marloes Hendrika ten Title: Individualized therapeutics in allogeneic stem

More information

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin Glossary of Terms This appendix is divided into two sections. The first section, General Terms, defines terms used throughout the CIBMTR data collection forms. The second section, FormsNet TM 2 Terms,

More information